SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing an increase of 256% compared to approximately $344,000 in the second quarter of 2026.
The substantial sequential increase in preliminary revenue reflects the successful commercial launch of REZENOPY™ and initial wholesale shipments, as well as continued sales growth and increasing market adoption of Arbli™. These results mark an important milestone in Scienture’s commercial expansion, reflecting the addition of a second FDA-approved product and continued progress toward building a diversified, multi-product pharmaceutical portfolio.
“These preliminary third-quarter revenue results mark a significant inflection point for Scienture, demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,” said CEO Narasimhan Mani. “With Arbli™ continuing to gain traction and REZENOPY™ becoming our second commercial-stage product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth through the remainder of 2026 and into 2027.
“As we work to expand our distribution channels and drive commercial adoption, we believe our historically high gross margins will provide significant operating leverage, supporting our goal of achieving profitability in 2027.”
SCNX shares gave up 16 cents, or 4.1%, to $3.75.
Related Stories
